3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Polycystic Ovary Syndrome
3
Neoplasms
2
Obesity
1
Leukemia, Myeloid, Acute
1
Hyperandrogenism
1
Heart Failure
1
Critical Illness
1
Cardiotoxicity
1
Acute Kidney Injury
1
Interventions
Trastuzumab
2
Ivabradine
2
Exercise
2
Echocardiography
2
Bisoprolol
2
salicylhydroxamic acid
1
sacubitril and valsartan sodium hydrate drug combination
1
mitoquinone
1
epicatechin gallate
1
dapagliflozin
1
candesartan
1
Trimetazidine
1
Therapeutics
1
Surveys and Questionnaires
1
Spironolactone
1
Silymarin
1
Secondary Prevention
1
Restraint, Physical
1
Ramipril
1
Radiotherapy
1
Perindopril
1
Neoadjuvant Therapy
1
Nebivolol
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Fluorouracil
1
Epirubicin
1
Docetaxel
1
Cyclophosphamide
1
Cisplatin
1
Carvedilol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Cardiotoxicity
×
Spironolactone
×
Clear all
NCT06005259
2023-08-22
SPIROTOX
University of Sao Paulo
Phase 4
Unknown
264 enrolled